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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
low-level laser therapy is an effective treatment for patients with primary Raynaud’s
Phenomenon.
STUDY DESIGN: Review of three randomized, double blind, placebo controlled trials,
published between 2002-2004.
DATA SOURCES: Randomized, double blind clinical trials comparing low-level laser
therapy with a placebo treatment were found using the Cochrane databases, and PubMed.
OUTCOME MEASURED: Reduction in frequency and severity of Raynaud’s attacks.
Outcomes were measured and recorded with daily diaries of attacks before and after the
intervention, and thermographic studies.
RESULTS: Three RCTs were included in this review. The RCT by Hirschl et al. 2002,
showed a decrease in frequency of attacks from 0.86 to 0.67 with the laser therapy, which
was more than with the sham treatment, but not statistically significant. It was, however,
significant in lowering the intensity of attacks. The RCT by Hirschl et al. 2004 showed
that both the number of attacks and their intensity were significantly reduced during the
period of laser therapy compared to the sham treatment. Intensity of attacks was reduced
82% with laser therapy. The RCT by Al-Awami et al. 2004, also showed a statistically
significant improvement in both frequency and intensity of attacks.
CONCLUSIONS: All three RCTs showed that low level laser therapy decreased the
frequency or intensity of Raynaud’s attacks more effectively than when exposed to a
sham treatment, and it seems to be an option for treating these attacks. Further studies
should be conducted to understand the pathogenetic mechanism of LLLT on Raynaud’s
phenomenon and it’s place in treatment.
Key Words: primary Raynaud’s phenomenon; low-level laser therapy
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INTRODUCTION
Raynaud’s is a disorder in which small blood vessels of the extremities have reduced
blood flow when they are exposed to cold, or emotional distress. Under these conditions, the
blood vessels go into spasms, causing pain, numbness, throbbing or tingling. Typically, the
fingers are most commonly affected, changing from white and even blue within minutes of
exposure, and then becoming red after being warmed. Primary Raynaud’s is not linked to an
underlying medical condition, whereas secondary Raynaud’s is associated with another condition
or disease, usually rheumatic in nature.1 Although Raynaud’s phenomenon is often self-limiting,
vasodilator drugs have been used in severe cases where it interferes with the person’s life.
However, these drugs many times have restrictions; such as lack of consistency, tolerance
development and side effects that may become intolerable for the patients.2 This paper evaluates
three randomized controlled trials (RCTs) comparing the efficacy of low-lever laser therapy
(LLLT) with no treatment, with the ultimate goal of reduction in frequency and intensity of
Raynaud’s attacks.
Raynaud’s attacks affect up to 10% of the adult population, hence making it relevant to
all healthcare providers, including physician assistants in practice. It tends to target females more
than males.2 During a Raynaud’s attack, the pallor of the digits, that cause cyanosis, pain and
numbness, lead to a decreased quality of life, and restrict patients from performing certain
activities or occupations.2,3 The cost of this condition has not been determined due to the fact that
only 1 in 5 people with this condition are aware that it is medically related and actively seek
treatment.1 The condition may be mild and not affecting their daily lives, and they may simply
attribute it to having poor circulation or being sensitive to cold climates.1 Many will often
present to a primary care doctor and be referred to a rheumatologist.1
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Primary Raynaud’s phenomenon is often a benign disease, but it often reduces a patient’s
quality of life. The underlying pathogenic process in Raynaud’s phenomenon is unclear.2 Studies
suggest the possibility of endothelial dysfunction. It has been shown that there are increased
levels of endothelial function and platelet activation, including the release of endothelin and vonWillebrand factor. These factors reduce the endothelial release of nitric oxide, leading to the
proposition that Raynaud’s phenomenon could have to do with endothelial-dependent
vasoregulation.2
Current methods used to treat this condition include self-limiting treatment, which is
simply keeping warm, and putting extremities under warm water2. However, this is not treatment
enough for many people. Biofeedback has also been tried with limited results.4 Vasodilator drugs
have been used with some success, including calcium channel blockers and α- adrenergic
blockers. However, most of these drugs have side effects or limitations, including lack of
consistency, development of tolerance, development of side effects including dizziness,
headaches, palpitations, and orthostatic hypotension.2 For this reason, low-level laser treatment is
being proposed. The use of low-level laser therapy has been shown to improve patient’s
complaints in frequency and severity or attacks compared to placebo treatment without the side
effects.2
OBJECTIVE
The objective of this selected EBM review is to determine whether or not low-level laser
therapy is an effective treatment for patients with primary Raynaud’s phenomenon.
METHODS
Criteria for selection of studies included patients with primary Raynaud’s
phenomenon. The intervention used was low-level laser therapy, and was compared with no
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treatment, which in this case was a sham laser. The outcomes measured in these studies were the
reduction in frequency and severity of Raynaud’s attacks in patients with primary RP. The
studies included in this EBM review include 3 RCTs comparing LLLT with no treatment.
Key words used in searches included: primary Raynaud’s phenomenon and low-level
laser therapy. Two articles were first published in German: M. Hirschl et al. Double-blind,
randomized, placebo controlled low level laser therapy study; and M. Al-Alwami et al, Low
Level laser therapy for treatment of RP. One article was published in English: Hirschl et al:
Laser therapy in RP. All articles were published in peer-reviewed journals. Literature searches
occurred via Cochrane databases and PubMed. Articles were selected based on importance of
outcomes to the patient (POEMS). Inclusion criteria included patients with primary Raynaud’s
phenomenon (RP). The diagnosis of primary RP was established by the exclusion of associated
disease or known cause for RP. Patients under the age of 18 were excluded, those over the age of
65, and those women of childbearing age not using adequate contraception. Also, patients could
not be using any vasoactive medication. Summary of statistics reported or used were p-values,
Wilcoxon paired test, ANOVA, Chi-square, Bartlett test, and the Kolmogorov-Smirnov test.
Table 1 demonstrates the demographics included in the studies.

Ruiz: Low-Level Laser Therapy and Primary Raynaud’s Phenomenon 4
Table 1: Demographics and characteristics of included studies
Study
M. AlAwam
i, 2004

Type #
Pts
RCT 47

Age Inclusion Criteria
yrs
18- Patients with RP for
65
2 yrs or more and at
least 4 episodes of
RP per week.
Established dx of
RP, by exclusion of
associated diseases
that cause
secondary RP.

Exclusion
Criteria
Any patients
taking
vasodilator
drugs. Patients
under the age of
18, over the age
of 65, and
women of
childbearing age
not using
adequate
contraception.

W/D

Interventions

0

RCT

15

3670

Patients with
established primary
RP

3

RCT

48

3260

Patients diagnosed
with primary RP
according to
diagnostic clinical
criteria. Patients
unassociated with
other diseases.

Patients must be
part of a longterm study,
selected during
the cold season
of Dec. 2000March 2001, in
which diagnostic
procedures for
detection of
underlying
diseases and
follow-up
control
established, for
exclusion of
secondary RP
Patients could
not use
vasoactive
medications
Patients taking
vasoactive
medication that
could interfere
with vascular
response

10 sessions of low
level laser distant
irradiation
treatment.
Exposure time:
1000 sec per
session, intensity:
400 mW, power
density 2.2 mW
per square cm
applied to palms
and fingers of
both hands
simultaneously
3-week period of
diode array (low
level laser 200
mW, wavelength
625 nm) for 30-40
min, 5 times per
week.

2

M.
Hirsch
l, 2002
3

Hirsch
l, 2004
4

2

3 week period of
diode laser
(power 200 mW,
wavelengths 685
nm) for 30-40
min, 5 times per
week
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OUTCOMES MEASURED
The outcomes measured included the reduction in frequency and severity of Raynaud’s
attacks. The outcomes were measured in all the studies with recorded daily diaries of attacks
before and after the intervention. Thermographic studies were also performed before in the study
by Al-Alwami. The thermographic study was done before the start of the trial and 6 weeks after
the irradiation. A standardized cold-warm challenge test using computerized thermography of
continuous temperature recordings was performed. The basal finger-tip skin temperatures was
performed after being in room temperature for 20 min; after 1 min. warm challenge (immersion
of gloved hand in water at 39° C), and after 1 min. cold challenge (immersion of gloved hand in
water at 20° C).
RESULTS
The three randomized controlled trials in this review were all presented in continuous
data. None of the data was dichotomous and could not be converted to dichotomous data.
Al. Alwami et al. 2004, presented all continuous data, used Chi-square to compare
proportions, and considered p-value < 0.05 as statistically significant. Paired continuous
variables were compared by Wilcoxon paired test. Overall, the frequency and severity of patients
with RP was reduced with LLLT (frequency p < 0.0001, severity p < 0.0001), better than with
placebo (frequency p < 0.0001, severity p < 0.02). In addition, there was a significant
improvement in frequency and severity at 6 weeks (frequency p = 0.007, severity p = 0.02) and 3
months (frequency p = 0.02, severity p = 0.04), as shown in Table 2.

Table 2: Comparison of the frequency and severity of RP attacks before and after LLLT
and placebo treatment (tx)
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Baseline
Frequency of RP
Severity of RP
6 weeks after tx
Frequency of RP
Severity of RP
3 months after tx
Frequency of RP
Severity of RP
P-value
Frequency of RP
Severity of RP

LLLT group (n =
24)

Placebo group (n= 23)

P-value

7
6

7
5

0.8
0.5

3
1

5
4

0.007
0.02

3
0

6
4

0.02
0.04

< 0.0001
< 0.0001

<0.0001
0.02

Improvement in thermographic response to cold challenge was only seen in patients
treated with LLLT and not seen in patients treated with placebo, as can be seen in Table 3. There
were no adverse effects or safety concerns in patients treated with LLLT.
Table 3: Temperatures of patients measured during cold challenge test, before and 6
weeks after LLLT and placebo
LLLT group (n = 24) C°
Placebo group (n = 23) C°
Cold challenge test- baseline
Temperature difference after
-2.3 °
-2.5 °
20 min recovery
Cold challenge test – 6 weeks
Temperature difference after
-0.6 °
-1.0 °
20 min recovery
P-value
0.02
0.1

Hirschl et al. 2002, presents the frequency and severity of attacks statistically by using
the Bartlett’s tests and the Kolmogorov-Smirnov test. For all statistical comparisons, a p-value
less than 0.05 was considered significant. Table 4 shows frequency of attacks of Raynaud’s
attacks during the 3 weeks of LLLT or placebo. Relative frequency of RP attacks was reduced
from 0.86 in week 1, to 0.67 in week 3 of LLLT, compared to the placebo with 0.90 in week 1 to
0.72 in week 3.
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Table 4: Relative frequency of attacks during the 3 weeks of LLLT or placebo therapy
Week 1
Week 2
Week 3
Laser
0.86 +/- 0.93
0.69 +/- 0.46
0.67 +/- 0.42
Placebo
0.90 +/- 0.83
0.86 +/- 0.67
0.72 +/- 0.32

Even though the frequency of attacks did decrease with LLLT, it was not statistically
significant (p = 0.520). Table 5 shows the average intensity for each week, which did decrease
significantly. In spite of this, there was no residual effect of LLLT after the third week, when no
treatment was implemented; hence the effects of the laser therapy may only be of short duration.
Table 5: Mean Intensity of symptoms measured on a 5-point scale before treatment
and at end of weeks 1 -3 of laser and placebo therapy
Pre-Treatment
Week 1
Week 2
Week 3
Laser
3.3
2.5
2.5
2.6
Placebo
3.3
3.0
3.0
3.2

Hirschl et al. 2004, uses ANOVA to compare laser and placebo conditions,
controlling for sequence of conditions to assess for potential differences across experimental
conditions. Normality was assessed by the Kolmogorov-Smirnov tests. Ambient temperature was
statistically not different between sham and laser exposure (sham 3.2 +/- 3.6 C°; laser 3.0 +/- 3.9
C°). Table 6 shows the frequency and the severity of attacks were significantly reduced during
the LLLT compared to the sham treatment. Intensity of attacks was reduced with placebo was
only slightly reduced (96% of pre-treatment intensity), compared to the results with the laser
therapy (82% of pre-treatment intensity). Table 6 also shows that exposure or evoking conditions
(cold, wetness, etc.) did not differ between pre-treatment phase and laser and place therapy
phase, which where each 3 weeks. Although all measures were favorable for LLLT, none of
them reached statistical significance, as shown by Table 6.
Table 6: Mean of average number of exposures per day, attacks per day, intensity of
attacks (5-point scale, minimal to severe; absolute and relative to week preceding
treatment) for each week of laser and placebo treatment
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Exposure
Attacks
Attacks
relative to
exposure
Intensity
Intensity
relative to
pretreatment

Pre
3.0
2.5
90

1
3.0
1.8
72

Laser
2nd
2.9
1.6
66

3.2

2.5
87

2.3
80

st

rd

3
2.9
1.6
66

2.3
78

1
2.9
2.1
83

Placebo
2nd
3.0
2.2
82

3rd
2.9
2.0
78

P
0.881
0.001
0.008

2.9
96

2.8
96

2.8
94

< 0.001
< 0.001

st

DISCUSSION
The study by Al-Awami was a double-blind placebo controlled trial, which showed that
LLLT resulted in more significant improvement in the symptoms of Raynaud’s attacks, when
compared with the placebo treatment. Even though there was an improvement in frequency and
severity in RP attacks, there was also some improvement with the placebo treatment. This shows
possible psychological influence. However, LLLT had a more significant improvement of patient
complaints. There was also a thermographic improvement that the placebo treatment did not
have. In terms of demographics, the diversity among patients with RP is a weakness in the trial,
with patients ranging from 18-65 years old. There were no noted side effects during the trial with
LLLT, making the efficacy of this laser treatment more appealing in the treatment of primary
RP.
The study by Hirschl et al. 2002, demonstrates that ultimately the frequency of attacks is
only slightly influenced by LLLT, and not statistically significant. However, severity of attacks
is statistically significantly reduced. Despite the randomized crossover design of the trial, the
psychological effect of patient expectations must be considered. Unfortunately, the slightly
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positive effects of LLLT are only in short duration, and there was no transfer effect from laser to
sham condition.
Finally the study by Hirschl et al. 2004, also using a crossover design, using each subject
as their own control, showed that frequency and intensity of attacks was reduced by a clinically
significant amount. The study demonstrated that patients with cold as the only trigger, and
patients that have a more pronounced temperature decrease, showed a better response to LLLT.
This may suggest an intrinsic heterogeneity of the clinical presentation of primary RP, and
differential therapeutic effects based on the differing intensity of vasospasms after cold
provocation. This could possibly be due to endothelium- independent factors, a current theory of
the pathogenesis of RP that must be further studied. Even though there was a beneficial effect
with placebo, the effects failed to reach statistical significance, while those treated with LLLT
had a substantial therapeutic effect in this trial. Although LLLT seems promising, there may not
be much more than scientific interest to overcome the shortage of available resources that would
make this treatment clinically effective.
CONCLUSION
Based on the studies reviewed, low-level laser therapy appears to be an effective
treatment in treating patients with primary Raynaud’s phenomenon. Even though there were
some improvements seen in the placebo groups as well, attributing some of the improvements to
psychological effect, those subjects treated with LLLT had a more significant therapeutic effect
in all of the trials. In addition, none of the studies showed side effects or undesirable outcomes,
demonstrating that LLLT is a safe and effective alternative to the current treatments for those
with primary Raynaud’s phenomenon. The trials, however, showed the effects of LLLT to be of
short-term benefit, and not necessarily a permanent or long duration treatment.
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The underlying mechanism of action of LLLT is still unknown, and further studies should
be implemented to determine this mechanism, whether it is due to endothelium-independent
factors or not. Also providing more insight into the mechanism of action of LLLT may help in
promoting endurance in the effects of this therapy. More knowledge in this area may help make
this treatment one that is more desirable and help overcome the possible shortage of available
resources that forms a barrier to making this an efficient and effective treatment for those
patients with primary Raynaud’s phenomenon.
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